Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Signaling networks in cholangiocarcinoma molecular pathogenesis, targeted therapies and drug resistance

Abstract : Cholangiocarcinoma (CCA) is a deadly disease. While surgery may attain cure in a minor fraction of cases, therapeutic options in either the adjuvant or advanced setting are limited. The possibility of advancing the efficacy of therapeutic approaches to CCA relies on understanding its molecular pathogenesis and developing rational therapies aimed at interfering with oncogenic signaling networks that drive and sustain cholangiocarcinogenesis. These efforts are complicated by the intricate biology of CCA, which integrates not only the driving force of tumor-cell-intrinsic alterations at the genetic and epigenetic level, but also pro-tumorigenic cues conveyed to CCA cells by different cell types present in the rich tumor stroma. Herein, we review our current understanding of the mechanistic bases underpinning the activation of major oncogenic pathways causative of CCA pathogenesis. We subsequently discuss how this knowledge is being exploited to implement rationale-based and genotype-matched therapeutic approaches that predictably will radically transform CCA clinical management in the next decade. We conclude by highlighting mechanisms of therapeutic resistance in CCA and reviewing innovative approaches to combat resistance at the pre-clinical and clinical level.
Liste complète des métadonnées

Littérature citée [219 références]  Voir  Masquer  Télécharger

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02087897
Déposant : Laurent Jonchère <>
Soumis le : vendredi 14 juin 2019 - 10:21:00
Dernière modification le : jeudi 14 janvier 2021 - 11:29:48

Fichier

Fouassier et al-Signaling netw...
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Laura Fouassier, Marco Marzioni, Marta B Afonso, Steven Dooley, Kevin Gaston, et al.. Signaling networks in cholangiocarcinoma molecular pathogenesis, targeted therapies and drug resistance. Liver International, Wiley-Blackwell, 2019, Cholangiocarcinoma, 39 (S1), pp.43-62. ⟨10.1111/liv.14102⟩. ⟨hal-02087897⟩

Partager

Métriques

Consultations de la notice

213

Téléchargements de fichiers

221